China Resources Double-Crane PharmaceuticalLtd Toekomstige groei

Future criteriumcontroles 1/6

China Resources Double-Crane PharmaceuticalLtd zal naar verwachting groeien in winst en omzet met respectievelijk 17.3% en 9.7% per jaar. De winst per aandeel zal naar verwachting groeien met 17% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.2% zijn.

Belangrijke informatie

17.3%

Groei van de winst

17.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	19.4%
Inkomstengroei	9.7%
Toekomstig rendement op eigen vermogen	13.2%
Dekking van analisten	Low
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

Oct 21

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Sep 30

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

Winst- en omzetgroeiprognoses

SHSE:600062 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	13,252	2,159	N/A	2,600	2
12/31/2025	13,055	1,933	N/A	2,321	3
12/31/2024	12,017	1,763	N/A	1,873	3
9/30/2024	10,322	1,348	1,082	1,840	N/A
6/30/2024	10,308	1,395	1,207	1,801	N/A
3/31/2024	10,285	1,374	1,201	1,812	N/A
12/31/2023	10,222	1,333	1,026	1,631	N/A
9/30/2023	10,916	1,584	1,296	1,811	N/A
6/30/2023	10,558	1,428	1,028	1,514	N/A
3/31/2023	9,880	1,223	888	1,357	N/A
12/31/2022	9,625	1,180	890	1,416	N/A
9/30/2022	9,394	1,025	611	1,258	N/A
6/30/2022	9,392	1,078	720	1,337	N/A
3/31/2022	9,222	981	618	1,198	N/A
12/31/2021	9,112	936	849	1,341	N/A
9/30/2021	9,006	1,021	904	1,269	N/A
6/30/2021	8,987	1,046	964	1,328	N/A
3/31/2021	8,730	1,016	956	1,318	N/A
12/31/2020	8,504	1,005	1,012	1,360	N/A
9/30/2020	8,348	1,010	956	1,238	N/A
6/30/2020	8,663	971	1,068	1,323	N/A
3/31/2020	8,930	1,001	1,123	1,347	N/A
12/31/2019	9,381	1,055	1,198	1,440	N/A
9/30/2019	9,322	1,043	1,192	1,430	N/A
6/30/2019	9,003	1,024	1,195	1,428	N/A
3/31/2019	8,720	997	1,289	1,541	N/A
12/31/2018	8,225	969	1,240	1,469	N/A
9/30/2018	7,975	962	1,386	1,589	N/A
6/30/2018	7,434	905	N/A	1,406	N/A
3/31/2018	7,032	908	N/A	1,271	N/A
12/31/2017	6,422	843	N/A	1,187	N/A
9/30/2017	6,103	838	N/A	1,071	N/A
6/30/2017	5,725	801	N/A	1,107	N/A
3/31/2017	5,584	767	N/A	911	N/A
12/31/2016	5,495	714	N/A	771	N/A
9/30/2016	5,490	705	N/A	828	N/A
6/30/2016	5,414	684	N/A	775	N/A
3/31/2016	5,274	645	N/A	813	N/A
12/31/2015	5,138	661	N/A	701	N/A
9/30/2015	5,733	865	N/A	1,025	N/A
6/30/2015	5,562	832	N/A	1,016	N/A
3/31/2015	5,413	785	N/A	876	N/A
12/31/2014	5,153	737	N/A	929	N/A
9/30/2014	4,276	776	N/A	674	N/A
6/30/2014	5,184	845	N/A	539	N/A
3/31/2014	6,010	859	N/A	637	N/A
12/31/2013	6,835	871	N/A	546	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 600062 ( 17.3% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 600062 ( 17.3% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.3% per jaar).

Hoge groeiwinsten: De winst van 600062 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 600062 ( 9.7% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 14% per jaar).

Hoge groei-inkomsten: De omzet van 600062 ( 9.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 600062 zal naar verwachting over 3 jaar laag zijn ( 13.2 %).

China Resources Double-Crane PharmaceuticalLtd Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Consensus EPS estimates increase by 11%

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 26% to CN¥24.32

Price target increased to CN¥19.26

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 3Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 15%

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Consensus EPS estimates increase by 11%

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven